
	<!DOCTYPE html>
	<html>
		<head>
			<title>【华泰医药代雯团队】荣昌生物：III期揭盲，泰它西普验证SLE疗效</title>
			<meta charset="utf-8" />
		</head>
		<body>
			<div class="note-wrapper">
				<h1>【华泰医药代雯团队】荣昌生物：III期揭盲，泰它西普验证SLE疗效</h1>
				<button class="btn btn-primary"><a href="../index.html">返回主页</a></button><br><br>
				【华泰医药代雯团队】荣昌生物：III期揭盲，泰它西普验证SLE疗效<br><br>9月19日，公司披露其核心产品泰它西普的国内SLE III期验证性临床研究的初步数据：合计335名患者纳入III期临床研究，给药52周后，FAS（全分析集）数据显示，接受泰它西普治疗患者的SRI-4反应率显著高于接受安慰剂的患者（82.6% vs 38.1%，P&lt;0.001），该研究达到主要终点。泰它西普进一步验证了其作为SLE（系统性红斑狼疮）领域best-in-class的潜力。<br><br>III期疗效验证II期获益<br>本次III期临床研究数据进一步验证了泰它西普在SLE患者中的显著疗效：1）II期关键临床研究中，FAS数据分析显示泰它西普160mg剂量组的48周SRI反应率为68.3%，显著优于安慰剂组（33.9%），改善达到34.4pp，而III期临床中泰它西普本身的SRI-4反应率（82.6%）还是较安慰剂的改善（44.5pp）均更有优势，获益趋势与II期临床相似；2）II期临床160mg剂量组和安慰剂组合计纳入患者125名，III期临床在更大样本（335名）的基础上同样获得临床优效结果。<br><br>泰它西普初步展现全球best-in-class潜力<br>目前全球尚无SLE生物药的头对头研究，但本次III期临床再次验证了泰它西普较其他已获批或临床后期竞品的潜在优势：1）BLyS单抗贝利尤单抗以国内患者为主的III期临床研究中，试验组和对照组的SRI-4反应率分别为53.8%和40.1%，试验组改善13.7pp；2）2021年被美国FDA获批治疗SLE的anifrolimab在全球III期临床TULIP-1中的SRI-4反应率为36.1%，低于安慰剂组的40.2%。<br><br>循证医学证据强化，或加速泰它西普国内商业化放量进程<br>我们预计公司将于4Q22提交泰它西普治疗SLE的完全获批上市申请。考虑到泰它西普本次在大样本临床研究中展现的疗效，我们认为其治疗SLE的循证医学证据更加坚实，有望促进其在医院的使用，加速商业化放量速度。截至6M22，公司自免商业化团队达241人，队伍持续壮大，泰它西普实现337家医院和717家双通道药房的准入。另一方面，泰它西普的新适应症拓展进展稳健，我们预计公司有望于年内启动泰它西普治疗IgA肾病和干燥综合症的国内III期临床研究并完成治疗类风湿关节炎的国内III期临床研究。<br><br>代雯/袁中平<br><br>#文字纪要#
				<br><br><button class="btn btn-primary"><a href="../index.html">返回主页</a></button>
	
			</div>
			<script type="text/javascript">
				(function() {
	
		var doc_ols = document.getElementsByTagName("ol");
	
		for ( i=0; i<doc_ols.length; i++) {
	
			var ol_start = doc_ols[i].getAttribute("start") - 1;
			doc_ols[i].setAttribute("style", "counter-reset:ol_counter " + ol_start + ";");
	
		}
	
	})();
	
			</script>
			<style>
				html,body,div,span,applet,object,iframe,h1,h2,h3,h4,h5,h6,p,blockquote,pre,a,abbr,acronym,address,big,cite,code,del,dfn,em,img,ins,kbd,q,s,samp,small,strike,strong,sub,sup,tt,var,b,u,i,center,dl,dt,dd,ol,ul,li,fieldset,form,label,legend,table,caption,tbody,tfoot,thead,tr,th,td,article,aside,canvas,details,embed,figure,figcaption,footer,header,hgroup,menu,nav,output,ruby,section,summary,time,mark,audio,video{margin:0;padding:0;border:0;font:inherit;font-size:100%;vertical-align:baseline}html{line-height:1}ol,ul{list-style:none}table{border-collapse:collapse;border-spacing:0}caption,th,td{text-align:left;font-weight:normal;vertical-align:middle}q,blockquote{quotes:none}q:before,q:after,blockquote:before,blockquote:after{content:"";content:none}a img{border:none}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}*{-moz-box-sizing:border-box;-webkit-box-sizing:border-box;box-sizing:border-box}html{font-size:87.5%;line-height:1.57143em}html{font-size:14px;line-height:1.6em;-webkit-text-size-adjust:100%}body{background:#fcfcfc;color:#545454;text-rendering:optimizeLegibility;font-family:"AvenirNext-Regular"}a{color:#de4c4f;text-decoration:none}h1{font-family:"AvenirNext-Medium";color:#333;font-size:1.6em;line-height:1.3em;margin-bottom:.78571em}h2{font-family:"AvenirNext-Medium";color:#333;font-size:1.3em;line-height:1em;margin-bottom:.62857em}h3{font-family:"AvenirNext-Medium";color:#333;font-size:1.15em;line-height:1em;margin-bottom:.47143em}p{margin-bottom:1.57143em;hyphens:auto}hr{height:1px;border:0;background-color:#dedede;margin:-1px auto 1.57143em auto}ul,ol{margin-bottom:.31429em}ul ul,ul ol,ol ul,ol ol{margin-bottom:0px}ol{counter-reset:ol_counter}ol li:before{content:counter(ol_counter) ".";counter-increment:ol_counter;color:#e06e73;text-align:right;display:inline-block;min-width:1em;margin-right:0.5em}b,strong{font-family:"AvenirNext-Bold"}i,em{font-family:"AvenirNext-Italic"}code{font-family:"Menlo-Regular"}.text-overflow-ellipsis{overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.sf_code_string,.sf_code_selector,.sf_code_attr-name,.sf_code_char,.sf_code_builtin,.sf_code_inserted{color:#D33905}.sf_code_comment,.sf_code_prolog,.sf_code_doctype,.sf_code_cdata{color:#838383}.sf_code_number,.sf_code_boolean{color:#0E73A2}.sf_code_keyword,.sf_code_atrule,.sf_code_rule,.sf_code_attr-value,.sf_code_function,.sf_code_class-name,.sf_code_class,.sf_code_regex,.sf_code_important,.sf_code_variable,.sf_code_interpolation{color:#0E73A2}.sf_code_property,.sf_code_tag,.sf_code_constant,.sf_code_symbol,.sf_code_deleted{color:#1B00CE}.sf_code_macro,.sf_code_entity,.sf_code_operator,.sf_code_url{color:#920448}.note-wrapper{max-width:46em;margin:0px auto;padding:1.57143em 3.14286em}.note-wrapper.spotlight-preview{overflow-x:hidden}u{text-decoration:none;background-image:linear-gradient(to bottom, rgba(0,0,0,0) 50%,#e06e73 50%);background-repeat:repeat-x;background-size:2px 2px;background-position:0 1.05em}s{color:#878787}p{margin-bottom:0.1em}hr{margin-bottom:0.7em;margin-top:0.7em}ul li{text-indent:-0.35em}ul li:before{content:"•";color:#e06e73;display:inline-block;margin-right:0.3em}ul ul{margin-left:1.25714em}ol li{text-indent:-1.45em}ol ol{margin-left:1.25714em}blockquote{display:block;margin-left:-1em;padding-left:0.8em;border-left:0.2em solid #e06e73}.todo-list ul{margin-left:1.88571em}.todo-list li{text-indent:-1.75em}.todo-list li:before{content:"";display:static;margin-right:0px}.todo-checkbox{text-indent:-1.7em}.todo-checkbox svg{margin-right:0.3em;position:relative;top:0.2em}.todo-checkbox svg #check{display:none}.todo-checkbox.todo-checked #check{display:inline}.todo-checkbox.todo-checked+.todo-text{text-decoration:line-through;color:#878787}.code-inline{display:inline;background:white;border:solid 1px #dedede;padding:0.2em 0.5em;font-size:0.9em}.code-multiline{display:block;background:white;border:solid 1px #dedede;padding:0.7em 1em;font-size:0.9em;overflow-x:auto}.hashtag{display:inline-block;color:white;background:#b8bfc2;padding:0.0em 0.5em;border-radius:1em;text-indent:0}.hashtag a{color:#fff}.address a{color:#545454;background-image:linear-gradient(to bottom, rgba(0,0,0,0) 50%,#0da35e 50%);background-repeat:repeat-x;background-size:2px 2px;background-position:0 1.05em}.address svg{position:relative;top:0.2em;display:inline-block;margin-right:0.2em}.color-preview{display:inline-block;width:1em;height:1em;border:solid 1px rgba(0,0,0,0.3);border-radius:50%;margin-right:0.1em;position:relative;top:0.2em;white-space:nowrap}.color-code{margin-right:0.2em;font-family:"Menlo-Regular";font-size:0.9em}.color-hash{opacity:0.4}.ordered-list-number{color:#e06e73;text-align:right;display:inline-block;min-width:1em}.arrow svg{position:relative;top:0.08em;display:inline-block;margin-right:0.15em;margin-left:0.15em}.arrow svg #rod{stroke:#545454}.arrow svg #point{fill:#545454}mark{color:inherit;display:inline;padding:0.2em 0.5em;background-color:#fcffc0}img{max-width:100%;height:auto}
			</style>
		</body>
	</html>
	